Please login to the form below

Procoralan

This page shows the latest Procoralan news and features for those working in and with pharma, biotech and healthcare.

The drug has been marketed for years in Europe by privately-held Servier under the Procoralan brand name.

FDA clears Amgen's Corlaner for heart failure

Corlaner is already on the market in Europe - where it is sold by privately held Servier as Procoralan and was approved to treat stable angina in 2005 and CHF in 2012.
Amgen gets priority review for chronic heart failure hope

require additional clinical trials, despite the fact that the drug is already sold (as Servier's Procoralan) for CHF and also stable angina in Europe.
Amgen throws its hat into the cholesterol antibody ring

Procoralan (ivabradine) from Servier in July.
Amgen drug misses endpoint in acute heart failure trial

a deal that involved Amgen obtaining US rights to Servier's chronic heart failure drug Procoralan (ivabradine).
Amgen buys US rights to Servier’s Procoralan

The major drug involved in the deal is Servier's Procoralan (ivabradine), which Amgen has obtained US rights to for an upfront fee of $50m plus undisclosed future milestones and royalties

More from news
Approximately 1 fully matching, plus 12 partially matching documents found.

Heart failure therapy embarks on a new era

has been sold for HF in Europe as Procoralan/Corlenter by originator Servier since 2012.
Deal Watch table for July 2013

100. ‡‡Servier / Amgen . Cardiovascular collaboration, licence and option. Procoralan (ivabradine, approved), S38844 (p2), omecamtiv mecarbil (p2).
Pharma deals during July 2013

Under this agreement, Servier has granted Amgen US rights to Procoralan (ivabradine), which is approved in Europe for chronic heart failure and stable angina in patients with elevated heart rates. ... Amgen is paying $50m upfront for US rights to

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Home based, Senior Medical Writer, Medical Communications: Excellent package

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

EU Head of Business Development and Client Service: Exceptional packge and bonus

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Associate Director – Social Healthcare – London: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Senior Account Executive – Account Manager – Healthcare Advertis...: £32000 - £43000 Bonus Benfits

Add my company

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

50 questions for delivering an exceptional healthcare brand experience: Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution: Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence: Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....